PubMed日本語 - 初期の成長応答3(egr3)は、再発性前立腺癌でなく非再発性前立腺癌で非常に過剰発現する。―QLifePro医療翻訳医療翻訳 QLifePro



Early growth response 3 (egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.

Published date 2013 Jan 14

Early growth response 3 (egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.


Published date



Rebecca Pio, Zhenyu Jia, Veronique T Baron, Dan Mercola,


Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America.


Members of the early growth response (EGR) family of transcription factors play diverse functions in response to many cellular stimuli, including growth, stress, and inflammation. Egr3 has gone relatively unstudied, but here through use of the SPECS (Strategic Partners for the Evaluation of Predictive Signatures of Prostate Cancer) Affymetrix whole genome gene expression database we report that Egr3 mRNA is significantly over-expressed in prostate cancer compared to normal prostate tissue (5-fold). The Human Protein Atlas (, a database of tissue microarrays labeled with antibodies against over 11,000 human proteins, was utilized to quantify Egr3 protein expression in normal prostate and prostate cancer patients. In agreement with the SPECS data, we found that Egr3 protein is significantly increased in prostate cancer. The SPECS database has the benefit of extensive clinical follow up for the prostate cancer patients. Analysis of Egr3 mRNA expression in relation to the relapse status reveals that Egr3 mRNA expression is increased in tumor cells of non-relapsed samples (n = 63) compared to normal prostate cells, but is significantly lower in relapsed samples (n = 38) compared to non-relapse. The observations were confirmed using an independent data set. A list of genes correlating with this unique expression pattern was determined. These Egr3-correlated genes were enriched with Egr binding sites in their promoters. The gene list contains inflammatory genes such as IL-6, IL-8, IL1β and COX-2, which have extensive connections to prostate cancer.


Egr3は比較的未研究になった、しかし、ここではSPECS(Prostate CancerのPredictive SignaturesのEvaluationのための戦略的なパートナー)Affymetrix全体ゲノム遺伝子発現データベースを用いることにより、我々はEgr3 mRNAが正常な前立腺の組織(5倍)と比較して前立腺癌で有意に過剰発現すると報告する。
Human Proteinアトラス(,000以上のヒト・タンパク質に対して抗体についてのラベルがついている組織マイクロアレイのデータベース)は、正常な前立腺と前立腺癌患者のEgr3タンパク質表現を定量化するために利用された。
再発の状態に関するEgr3 mRNA発現の分析で、Egr3 mRNA発現が正常な前立腺の細胞と比較して非再発検体(n = 63)の腫瘍細胞で増加するが、非再発と比較して再発試料(n = 38)が有意により少ないことが分かる。

460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳